Compare Cassava Sciences Inc (FLNA) vs Direxion Daily S&P 500 Bull 3X Shares (SPXL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Direxion Daily S&P 500 Bull 3X Shares — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Direxion Daily S&P 500 Bull 3X Shares trades at $297.97 (market cap $7.36B). The key difference: Direxion Daily S&P 500 Bull 3X Shares is far larger — about 186.8× Cassava Sciences Inc's market cap, and Direxion Daily S&P 500 Bull 3X Shares is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Direxion Daily S&P 500 Bull 3X Shares for 32 Days on average.
| FLNA | SPXL | |
|---|---|---|
Market Cap | $39.40M | $7.36B |
Volume | 759,018 | 1,835,467 |
Sector | Health | Leveraged / Inverse |
52-Week High | $4.64 | $301.38 |
52-Week Low | $0.68 | $170.20 |
Typical Hold Time | 37 Days | 32 Days |
Enterprise Value | -$43.28M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8136, down 0.26% with a bearish technical signal. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates for three consecutive quarters. Recent positive FDA news regarding the clinical hold lift on simufilam for epilepsy research provides a potential catalyst. Cash flow remains negative with net cash flow of -$33.07M in 2025.
The outlook is mixed with strong analyst support (66.7% buy ratings) against fundamental challenges. Investment opportunity lies in clinical trial success, while risks include sustained cash burn and execution hurdles. The stock's low EV/EBITDA of 1.03 and P/B of 0.62 suggest undervaluation if pipeline milestones are met.
SPXL trades at $293.05, down 1.28% on the day, with technical indicators showing a bullish trend from moving averages while oscillators remain neutral. The stock faces resistance at $297 and support at $289. Recent news highlights S&P 500 valuation concerns with earnings growth expected to slow from 35% in 2026 to 15% in 2027 according to Wall Street analysts.
The ETF's performance remains tied to S&P 500 momentum, with seasonal patterns and institutional positioning supporting potential upside. Key risks include market concentration in top holdings and geopolitical uncertainty. Analyst sentiment is mixed with expectations of continued growth but caution around valuation levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Direxion Daily S&P 500 Bull 3X Shares
SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.
Read more on SPXL →
